Company Highlights

Become a leading player in the Orphan Oncology field, leaning on an advanced product pipeline

  •  Breakthrough highly innovative products in diseases with strong unmet medical need
  • Advanced programs with results expected in the short/medium term (2014-2016)
  • Potential company changers with large sales potential (up to €800 M)